Novo Nordisk's London Reckoning: Can a Capital Markets Day Outrun the Doubters?
Published on 09/02/2026 at 18:41 | Editorial boerse-global.de
The arithmetic facing Novo Nordisk's management is unforgiving. Shares in the Danish drugmaker closed Tuesday at €38.99, leaving the stock 11 percent in the red since January and roughly 3 percent adrift of its 200-day moving average — the technical marker that often separates a corrective phase from a structural downtrend. Wednesday brought some relief, with the equity climbing 3.0 percent to €40.16, yet even that bounce leaves the shares 27 percent shy of the €54.86 peak touched at the start of the year.
That whipsaw action tells its own story. The 30-day volatility reading has climbed to 41 percent, a signal that investors are bracing for outsized moves in either direction. And the catalyst for those swings is fast approaching: a Capital Markets Day scheduled for September 21 in London, where the board intends to unveil fresh "Strategic Aspirations" for a company whose growth narrative has suddenly developed cracks.
A Downgrade That Landed on an Awkward Day
The skepticism hardening around Novo Nordisk is not abstract. Deutsche Bank analysts formally shifted their stance in late August, downgrading the stock from Hold to Sell and trimming their price objective to 265 Danish kroner from 290. Their reasoning was blunt: fading growth prospects for 2027, pipeline setbacks, and the long-term overhang of patent expiries on core products.
The timing was almost cruelly ironic. The downgrade landed on the same day Chinese regulators accepted the company's filing for the oral version of Wegovy — a development that should have been an unqualified positive, opening a route into the world's most populous market on top of existing approvals in the US, the UK, the EU, the UAE and Bahrain. That a regulatory milestone in China could not offset the bank's concerns speaks volumes about how far the debate has shifted from individual approval wins to the structural trajectory of the business.
The Pipeline Problem at the Heart of the Bear Case
What precisely is worrying the bears? The most concrete issue is ziltivekimab, an anti-inflammatory candidate that had been positioned as a future growth driver. Its late-stage study failed to hit the primary cardiovascular endpoint, eliminating what Deutsche Bank had explicitly flagged as a potential pillar of the growth forecast. With that candidate removed from the equation, the company's reliance on its GLP-1 franchise becomes more pronounced — precisely as competition in oral weight-loss therapies intensifies.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The numbers illustrate the pressure. In the second quarter of 2026, the Wegovy pill generated 3.22 billion kroner in revenue, marginally short of the 3.27 billion kroner analysts had penciled in. Meanwhile, Eli Lilly's oral contender, Foundayo, is gaining traction faster in its launch phase than Wegovy did in its own early weeks. Media reports put Foundayo at roughly 40,800 weekly prescriptions by its 20th week on the market, against Wegovy's approximately 57,000 in week six — a lead that is visibly narrowing with each passing month.
The prescription data cuts to the heart of the competitive question. Novo Nordisk has long enjoyed a duopoly with Eli Lilly in the weight-loss arena, but the oral segment is where that grip faces its sternest test. If the pill was meant to be the next growth engine, the early trajectory suggests the engine may not be firing as hard as hoped.
Not Everything Is Broken
To frame this purely as a story of decline would be misleading. The fundamentals, while cooling, remain respectable. Adjusted revenue grew 7 percent on a currency-neutral basis in the second quarter of 2026, with operating profit ahead 11 percent. Management responded by lifting full-year guidance, now modeling adjusted revenue between minus 6 percent and flat year-on-year at constant exchange rates — a range that at least implies stabilization rather than deterioration.
There are also signs of life beyond the core GLP-1 franchise. The oral Wegovy pill has already generated more than five million prescriptions since its January launch. The company's research engine continues to churn: a partnership with Novonesis on microbiome therapies is progressing, dose-finding studies on the oral semaglutide pill are underway, and Lexicon Pharmaceuticals — a collaborator on the obesity candidate LX9851 — received its third milestone payment of $10 million in 2026 after hitting a patient-dosing target.
These developments complicate the bearish narrative. Novo Nordisk is not retrenching; it is spending and partnering and filing. The question is whether any of it moves the needle enough to close the gap between what the company promises and what the market now expects.
What London Must Deliver
The stock currently trades within touching distance of its 200-day average of €40.18, a level that has effectively become the battleground between bulls and bears. Hold that line, and the stabilization scenario remains intact. Lose it decisively, and the path back toward the January high of €54.86 lengthens considerably.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
That makes the September 21 event in London less a presentation and more a test of credibility. Management needs to translate the second-quarter momentum — the Chinese filing, the prescription growth, the guidance raise — into a quantified medium-term framework that analysts can model and trust. What it cannot afford is another session of aspirational language without the numbers to back it up.
The market's patience is demonstrably finite. Deutsche Bank's downgrade was not an outlier provoked by a single data point but the crystallization of a broader concern: that Novo Nordisk's next act may not match its last one. The bull case rests on the idea that the current valuation — near the 200-day line, well off the highs — already discounts much of the bad news. The bear case rests on the equally plausible notion that the growth slowdown is still being priced in, not priced through.
September 21 will not settle the argument definitively. But it will tell investors which side of the trade has the better evidence. For a company that has spent years making the difficult look routine, the challenge now is making the routine — steady growth, a defended franchise, a credible pipeline — look possible again.
Ad
Novo Nordisk Stock: New Analysis - 2 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
